FibroidsNCT02954744
High-intensity Focused Ultrasound in Treatment of Uterine Fibroid
A study testing HIFU treatment in people with Fibroids, run by Queen Mary Hospital, Hong Kong.
Trial summary
Uterine fibroids are common uterine benign neoplasm. They can cause abnormal menstrual bleeding, pelvic discomfort and urinary frequency. Although surgical intervention is the definitive treatment, some women prefer to have their uterus preserved. Read more about this study
- Who is it for?
- Ages 30 to 60 years, women only
- Conditions the study is for
- Fibroids
- What is being tested?
- HIFU treatment
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- Mar 2012to Mar 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Age >40 years old, with no future childbearing plans
- Age >30 years old, who has tubal sterilization
- Significant fibroids symptoms
- Clinical uterine size less than 20 weeks gestation
- Dominant fibroid less than 10 cm in diameter without areas of necrosis as judged by contrast MRI
- No laparotomy scars
- Women should be able to give consent
Who cannot join
- Other pelvic or uncontrolled systemic diseases
- Confirmed or suspected pregnancy
- Patients who are contraindicated for MRI examination
- Patients with thick abdominal wall (>5 cm, as measured by MRI)
- Presence or history of acute pelvic inflammatory disease
- History of lower abdominal surgery, known severe pelvic endometriosis and/ or extensive pelvic adhesion
- Cervical fibroids, subserous or submucous fibroids with pedicle, <3.5 cm posterior wall fibroid, fibroids suspicious of malignancy (rapidly growing)
About this study
Official title: Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Fibroid
Uterine fibroids are common uterine benign neoplasm. They can cause abnormal menstrual bleeding, pelvic discomfort and urinary frequency. Although surgical intervention is the definitive treatment, some women prefer to have their uterus preserved. High-intensity focused ultrasound (HIFU) therapy is receiving increasing interest in the management of uterine fibroids by inducing focal thermocoagulation of the fibroids. Results obtained by various research groups have shown that HIFU treatment is safe, effective and is highly acceptable to patients. The main objective of this study is to evaluate the therapeutic efficacy of HIFU in the treatment of uterine fibroids.
In this proposed study, 20 patients who have symptomatic uterine fibroids who meet the study inclusion criteria will be invited to participate in the study which involves the use of HIFU in the management of the fibroid. Background information of the patients such as age, body mass index, hormonal (pre- or postmenopausal) status and the presence of chronic medical disease will be collected. Subjects will also be asked to complete an eight-item section of a Uterine Fibroid Symptom and Quality Of Life Questionnaire (UFS-QOL) which evaluate the effect of the fibroid on the quality of life of women.
- Conditions
- Fibroids
- Being tested
- HIFU treatment
- Keywords
- uterine fibroid
- Medical subject headings
- Leiomyoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HIFU treatmentProcedure or surgery
High intensity focused ultrasound
| Study group | Role | What they receive |
|---|---|---|
| Treatment arm | Experimental | HIFU treatment Receives: Procedure: HIFU treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy of HIFU in reducing the size of the uterine fibroids by sonographic measurements
By sonographic measurements at baseline, post 1-month, post 3-month, and post 12-month, the size of the uterine fibroids will be evaluated by physicians
Measured: The changes from baseline to post12-month treatment will be captured
Secondary outcomes (5)
Patient satisfaction score after HIFU treatment of uterine fibroid
Patients will be asked to give the satisfaction score (0= not satisfactory, 5= very satisfactory) at each follow up (i.e. post treatment 1 months, 3 months, 6 months and 12 months)
Measured: Up to 12 months
Change of perceived symptoms after HIFU treatment by using the Uterine Fibroid Symptoms Quality Of Life Questionnaire (UFS_QOL)
By using the Uterine Fibroid Symptoms Quality Of Life Questionnaire (UFS_QOL) at each follow up (i.e. from baseline to post 1- month, post 1-month to post 3-month, post 3-month to post 6-month, post 6-month to post 12-month treatment will be captured).
Measured: Up to 12 months
Risks and adverse effects of HIFU in the treatment of uterine fibroid
Patient will be evaluated for abnormal laboratory values and/or adverse events that are related to treatment at each follow up (i.e. post treatment 1 months, 3 months, 6 months and 12 months)
Measured: Up to 12 months
Subsequent management after HIFU treatment of uterine fibroid
By physician's judgment at each follow up (i.e. at post treatment 1 months, 3 months, 6 months and 12 months), the need for subsequent additional treatments (such as hysterectomy, uterine artery embolization, or any type of hormonal treatment) will be evaluated.
Measured: Up to 12 months
Efficacy of HIFU in reducing the size of the uterine fibroids by MRI measurements
By MRI measurements at baseline, post 6-month, the size of the uterine fibroids will be evaluated by physicians
Measured: The changes from baseline to post 6-month treatment will be captured
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2016 (estimated)
- Study startMar 2012
- Primary completionAug 2017
- Study completionMar 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FibroidsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen Mary Hospital, Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Vincent YT Cheung, Queen Mary Hospital, Hong Kong
- Investigators
- Vincent, YT Cheung, MBBS, FRCOG, Principal investigator, Queen Mary Hospital, Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02954744
- Sponsor's protocol ID
- UW11-204
- Status last verified
- Mar 2018
- First submitted
- 20 Oct 2016
- Last updated
- 5 Mar 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Fibroid
- ClinicalTrials.gov ID
- NCT02954744
- Acronym / sponsor ID
- UW11-204
- Conditions
- Fibroids
- Keywords
- uterine fibroid
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Queen Mary Hospital, Hong KongUniversity, hospital or other
- Study start
- Mar 2012
- Primary completion
- Aug 2017 (actual)
- Study completion
- Mar 2018 (actual)
- First posted
- 3 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Uterine fibroids are common uterine benign neoplasm. They can cause abnormal menstrual bleeding, pelvic discomfort and urinary frequency. Although surgical intervention is the definitive treatment, some women prefer to have their uterus preserved. High-intensity focused ultrasound (HIFU) therapy is receiving increasing interest in the management of uterine fibroids by inducing focal thermocoagulation of the fibroids. Results obtained by various research groups have shown that HIFU treatment is safe, effective and is highly acceptable to patients. The main objective of this study is to evaluate the therapeutic efficacy of HIFU in the treatment of uterine fibroids.
In this proposed study, 20 patients who have symptomatic uterine fibroids who meet the study inclusion criteria will be invited to participate in the study which involves the use of HIFU in the management of the fibroid. Background information of the patients such as age, body mass index, hormonal (pre- or postmenopausal) status and the presence of chronic medical disease will be collected. Subjects will also be asked to complete an eight-item section of a Uterine Fibroid Symptom and Quality Of Life Questionnaire (UFS-QOL) which evaluate the effect of the fibroid on the quality of life of women.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Treatment arm | Experimental | Procedure: HIFU treatmentHIFU treatment |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Age >40 years old, with no future childbearing plans
- Age >30 years old, who has tubal sterilization
- Significant fibroids symptoms
- Clinical uterine size less than 20 weeks gestation
- Dominant fibroid less than 10 cm in diameter without areas of necrosis as judged by contrast MRI
Key exclusion criteria (7 listed)
- Other pelvic or uncontrolled systemic diseases
- Confirmed or suspected pregnancy
- Patients who are contraindicated for MRI examination
- Patients with thick abdominal wall (>5 cm, as measured by MRI)
- Presence or history of acute pelvic inflammatory disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HIFU treatmentHigh intensity focused ultrasound | Procedure or surgery | Treatment arm |
Primary outcome
Efficacy of HIFU in reducing the size of the uterine fibroids by sonographic measurements
Time frame: The changes from baseline to post12-month treatment will be captured
By sonographic measurements at baseline, post 1-month, post 3-month, and post 12-month, the size of the uterine fibroids will be evaluated by physicians
5 secondary outcomes
Patient satisfaction score after HIFU treatment of uterine fibroid
Time frame: Up to 12 months
Change of perceived symptoms after HIFU treatment by using the Uterine Fibroid Symptoms Quality Of Life Questionnaire (UFS_QOL)
Time frame: Up to 12 months
Risks and adverse effects of HIFU in the treatment of uterine fibroid
Time frame: Up to 12 months
Subsequent management after HIFU treatment of uterine fibroid
Time frame: Up to 12 months
Efficacy of HIFU in reducing the size of the uterine fibroids by MRI measurements
Time frame: The changes from baseline to post 6-month treatment will be captured
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2018.
Related trials for Fibroids
Active, not recruiting
Prospective Study of TVRFA Treatment for FIGO Type 3-5 Uterine Fibroids
Leiomyoma (Uterine Fibroids)
RecruitingObservational study
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Renal Tumor Histology, Cutaneous Leiomyoma
Active, not recruiting
Life Study: Lifestyle Intervention in Fibroid Elimination
Uterine Fibroid
Not yet recruiting
Office Hysteroscopy Versus Operating-room Hysteroscopy for Uterine Lesions
Uterine Polyps, Uterine Fibroids
RecruitingObservational study
Predictors of Success and Failure of v-NOTES Hysterectomy for Large and Very Large Uteri
Uterine Fibroids, Hysterectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vincent, YT Cheung, MBBS, FRCOG principal investigator
Queen Mary Hospital, Hong Kong
Questions about this trial
What is this clinical trial studying?
A study testing HIFU treatment in people with Fibroids, run by Queen Mary Hospital, Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy of HIFU in reducing the size of the uterine fibroids by sonographic measurements (time frame: The changes from baseline to post12-month treatment will be captured). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2018.